V. Grünwald

Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)

A. Großhennig, V. Grünwald, M. Abbas, 2016, Medical Oncology.

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

V. Grünwald, H. Schmoll, J. Casper, 2004, Investigational New Drugs.

An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors

C. Bokemeyer, K. Oechsle, F. Mayer, 2007, Anti-cancer drugs.

Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney.

H. Kreipe, A. Merseburger, M. Kramer, 2015, Journal of the Egyptian National Cancer Institute.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

N. Reinmuth, L. Heinzerling, J. Trojan, 2017, Cancer treatment reviews.

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914).

R. Motzer, P. Russo, A. Bex, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)

R. Issels, J. Hartmann, I. Sturm, 2015, Investigational New Drugs.